Newsletter | September 5, 2025

09.05.25 -- New Podcast Episodes: Functional Antibody Screening, Safer Stem Cell Therapies, FDA Fridays

LISTEN NOW: OUR LATEST PODCAST EPISODES

Check out the latest episodes from Better BiopharmaCell & Gene: The Podcast, and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

WHO’S MOVING THE INDUSTRY FORWARD

Functional Antibody Screening With Abalone Bio's Richard Yu, Ph.D.

In this episode of "Better Biopharma," Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening.

Developing An In Vivo CAR-T With Interius BioTherapeutics' Sianny Christanti and Babu Medi, Ph.D.

Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.

Delivering Biologics To The Brain With Adaptin Bio's Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD

In this episode of "Better Biopharma," host Tyler Menichiello is joined by Adaptin Bio's CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD to discuss Adaptin's Brain Bispecific T-cell Engager (BRiTE) platform.

THE PODCAST FOR LEADERS OF EMERGING BIOPHARMA

The Generalist Biotech CEO With Seekyo's Oury Chetboun

Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing innovative solid tumor treatments that target functional proteins in the tumor micro-environment.

How To Hire And Build A Winning Executive Team With Occam Global's Bill Holodnak

Bill Holodnak, Cofounder and CEO of Occam Global, a life sciences executive recruitment firm (and occasional investor), shares insights from his decades of experience pairing executives with drug development companies, and talks about the psychology of successful biotech leadership.

Biotech Product Partnership With Coya Therapeutics' Arun Swaminathan, Ph.D. And Dr. Reddy's Milan Kalawadia

Milan Kalawadia, CEO, North America, Dr. Reddy's Laboratories, and Arun Swaminathan, Ph.D., CEO, Coya Therapeutics discuss their unique partnership to develop COYA 302, a novel dual-mechanism immunotherapy for the treatment of ALS. 

Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D.

Ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise.

VOICES FROM THE FRONT LINE OF CELL AND GENE DISCOVERY

Navigating The Journey To Safer Stem Cell Therapies With Orca Bio's Nate Fernhoff

 Cell & Gene: The Podcast Host, Erin Harris, talks to Orca Bio CEO and Co-Founder Nathaniel Fernhoff as he recounts the company’s origins and evolution, tracing its roots to pioneering stem cell research at Stanford University and Dr. Irv Weissman's lab.

FDA Fridays: Advancing Communication And Consistency In CGT Regulation With Kaye Spratt

This is Episode 1 of a special series of Cell & Gene: The Podcast, "FDA Fridays." This first episode features Host, Erin Harris' conversation with Kaye Spratt, Strategic and Non-Clinical Regulatory Consultant at Spratt Advanced Cell & Gene Therapy Regulatory Consulting.

Advancing Gene Therapy For FTD With Passage Bio's Dr. Will Chou

Host Erin Harris talks to Will Chou, M.D., CEO of Passage Bio about the promise and challenges of developing gene therapies for frontotemporal dementia (FTD), a neurodegenerative disease with strong genetic underpinnings.